RhumbLine Advisers
BCAX

RhumbLine Advisers’s Bicara Therapeutics BCAX Stock Holding History

RhumbLine Advisers’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.63M Buy
54,986
+14,239
+35% +$318K ﹤0.01% 2055
2026
Q1 		$810K Buy
40,747
+164
+0.4% +$2.82K ﹤0.01% 2309
2025
Q4 		$683K Sell
40,583
-5,036
-11% -$86K ﹤0.01% 2459
2025
Q3 		$720K Sell
45,619
-1,292
-3% -$14.5K ﹤0.01% 2447
2025
Q2 		$436K Buy
46,911
+23,893
+104% +$285K ﹤0.01% 2769
2025
Q1 		$300K Buy
23,018
+4,010
+21% +$53.3K ﹤0.01% 2891
2024
Q4 		$331K Buy
+19,008
New +$396K ﹤0.01% 2933

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RhumbLine Advisers's BCAX Position: Q2 2026 in Review

RhumbLine Advisers increased its Bicara Therapeutics (BCAX) stake by 35% in Q2 2026, buying an estimated $318K and bringing the position to 54,986 shares worth $1.63M. The position accounts for ﹤0.01% of the portfolio, ranked #2055.

RhumbLine Advisers first reported a position in BCAX in Q4 2024 and has held it in 7 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • RhumbLine Advisers held 54,986 shares of Bicara Therapeutics worth $1.63M as of Q2 2026.
  • RhumbLine Advisers bought 14,239 Bicara Therapeutics shares in Q2 2026, an estimated $318K.
  • Bicara Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2055 holding.
  • RhumbLine Advisers first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.